Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review
Authors:
Open Access
- 1 July 2012
- journal article
- review article
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. 5, 165-174
Abstract
Peer reviewed article authored by (Berlie H, Hurren KM, Pinelli NR). Read article or submit your manuscript for publishing.Keywords
This publication has 21 references indexed in Scilit:
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- Glucagon-like peptide analogues for type 2 diabetes mellitusCochrane Database of Systematic Reviews, 2011
- Cardiovascular Effects of Glucagonlike peptide–1 AgonistsThe American Journal of Cardiology, 2011
- Co‐administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interactionDiabetes, Obesity and Metabolism, 2010
- Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and MetforminDiabetes Care, 2010
- Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2009
- A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetesDiabetologia, 2008
- The biology of incretin hormonesCell Metabolism, 2006
- Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.Journal of Clinical Investigation, 1998
- Glucagon‐like peptide‐1 reduces hepatic glucose production indirectly through insulin and glucagon in humansActa Physiologica Scandinavica, 1997